Allspring Global Investments Holdings LLC Decreases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 21.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 52,617 shares of the biopharmaceutical company’s stock after selling 14,161 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Amicus Therapeutics were worth $747,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Amicus Therapeutics by 97.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 3,638 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at about $128,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at about $134,000. Los Angeles Capital Management LLC purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at about $158,000. Finally, O Shaughnessy Asset Management LLC lifted its holdings in shares of Amicus Therapeutics by 25.3% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 3,082 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have recently weighed in on FOLD shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a report on Thursday, February 29th. JPMorgan Chase & Co. dropped their price target on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, March 18th.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $10.54 on Thursday. The stock has a market capitalization of $3.11 billion, a PE ratio of -20.67 and a beta of 0.75. Amicus Therapeutics, Inc. has a 52-week low of $9.70 and a 52-week high of $14.57. The stock’s 50-day moving average price is $12.08 and its 200 day moving average price is $12.01. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 2.42.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The business had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. As a group, equities research analysts forecast that Amicus Therapeutics, Inc. will post 0.01 EPS for the current year.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 4,167 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $58,338.00. Following the transaction, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider David Michael Clark sold 4,427 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total value of $61,978.00. Following the sale, the insider now owns 253,664 shares in the company, valued at approximately $3,551,296. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bradley L. Campbell sold 4,167 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total value of $58,338.00. Following the completion of the sale, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,108 shares of company stock worth $662,605. Company insiders own 2.10% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.